Olema Pharmaceuticals, Inc. (OLMA) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 18%; Elevated put/call ratio: 11.14; Below-average business quality.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER... Read more
Sell if holding. Engine safety override at $13.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 18%; Elevated put/call ratio: 11.14; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Score 4.0/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Olema Pharmaceuticals, Inc.
Latest news
- Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35 — benzinga May 13, 2026 neutral
- Olema Pharmaceuticals Q1 EPS $(0.52) Beats $(0.53) Estimate — benzinga May 12, 2026 positive
- Olema Pharma To Present Phase 1 OP-3136 Data And Phase 3 OPERA-02 Trial Updates At ASCO 2026 — benzinga Apr 21, 2026 positive
- Olema Pharmaceuticals Reveals Preclinical Data For Palazestrant and OP-3136 At The 2026 AACR Annual Meeting; Palazestran — benzinga Apr 17, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 6.3% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 18%; Elevated put/call ratio: 11.14; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $12.25. Score 4.0/10, moderate confidence.
Take-profit target: $16.65 (+27.1% upside). Prior stop was $12.25. Stop-loss: $12.25.
DATA_ISSUE: analyst_target_implausible (raw $41.82 vs price $13.10 — ratio 3.2×). Rejected, falling back to technical TP.; Quality below floor (1.2 < 4.0).
Olema Pharmaceuticals, Inc. trades at a P/E of N/A (forward -5.5). TrendMatrix value score: 5.0/10. Verdict: Sell.
19 analysts cover OLMA with a consensus score of 4.3/5. Average price target: $42.
What does Olema Pharmaceuticals, Inc. do?Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and...
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.